This study is a single-centre, interventional randomised controlled trial. Participants will be individually randomised to receive either COMPASS online CBT + "usual care" (standard LTC charity support), or usual care only. Randomisation will be stratified by recruiting charity site to ensure a balance of participants with different LTCs across the intervention and control arm. Randomisation will occur using a 1:1 allocation ratio managed by RECAP software. Participants randomised to COMPASS will receive access to the online program. It consists of 11 online modules which target challenges associated with living with LTC(s) and includes, amongst other things, psycho-education, patient examples, interactive tasks and goal setting. Participants are linked to a therapist; 'guide', who will provide 6 x 30 minute support sessions delivered fortnightly in the format preferred by the client (phone and/or in-site message). Participants allocated to the usual care control arm will receive the usual care that is available to them via their charity. All charities include a helpline which can be accessed via telephone or email. The helplines at all charities offer one-off emotional and/or informational support provided by people trained in active listening and/or counselling skills. Additional support avenues that can be accessed may include online support groups, local community support groups and informational resources.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
194
An 11 module, therapist-supported online CBT program.
Resources provided by the charities involved, including supportive listening, online support groups, information resources and local community support groups.
Health Psychology Section
London, United Kingdom
Change in Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)
A composite measure of Generalised Anxiety Disorder questionnaire (GAD-7) and Patient Health Questionnaire (PHQ-9). Min score = 0, Max score = 48, with higher scores indicating higher levels of distress.
Time frame: At baseline, 6 weeks (mid-therapy) and 12 weeks (end of therapy)
Change in Work and social adjustment scale (WSAS)
Social functioning. Min score = 0, Max score = 40 , with higher scores indicating greater functional impairment.
Time frame: At baseline, 6 weeks (mid-therapy) and 12 weeks (end of therapy)
Change in EQ-5D-3L
Quality of life. Min score = 5, Max score = 15 , with higher scores more problems in the scale dimensions.
Time frame: At baseline, 6 weeks (mid-therapy) and 12 weeks (end of therapy)
Change in Illness perception questionnaire - revised (IPQ-R), emotional subscale
IPQ-R tailored to COVID-19 to establish emotional responses regarding the COVID-19 pandemic. Min score = 0, Max score = 24 , with higher scores indicating higher emotional responses.
Time frame: At baseline, 6 weeks (mid-therapy) and 12 weeks (end of therapy)
Change in Patient Health Questionnaire - (PHQ-9)
Depression. Min score = 0, Max score = 27, with higher scores indicating greater depression
Time frame: At baseline, 6 weeks (mid-therapy) and 12 weeks (end of therapy)
Change in Generalised Anxiety Disorder scale (GAD-7)
Anxiety. Min score = 0, Max score = 21, with higher scores indicating greater anxiety
Time frame: At baseline, 6 weeks (mid-therapy) and 12 weeks (end of therapy)
Change in bespoke illness-related distress measure (2 items)
Illness-related distress. Developed by research team. Min score = 0, Max score = 6, with higher scores indicating greater distress.
Time frame: At baseline, 6 weeks (mid-therapy) and 12 weeks (end of therapy)
Change in Patient Activation Measure (PAM) short version (13 items).
Assess knowledge and confidence in illness self-management. Min score = 0, max score = 100, with higher scores indicating greater levels of knowledge and confidence.
Time frame: At baseline, 6 weeks (mid-therapy) and 12 weeks (end of therapy)
The Patient Global Impression Scales of Severity (PGI-S)
Perceived symptom severity. 1 item. Min = 0, Max = 3, with higher scores indicating greater perceived symptom severity.
Time frame: At baseline, 6 weeks (mid-therapy) and 12 weeks (end of therapy)
The Patient Global Impression Scales of Improvement (PGI-I)
Perceived symptom improvement. 1 item. Min = 0, Max = 6, with higher scores indicating greater perceived symptom deterioration.
Time frame: 6 weeks (mid-therapy) and 12 weeks (end of therapy)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.